-+ 0.00%
-+ 0.00%
-+ 0.00%

EVOMMUNE SHARES DOWN 28% AFTER THE BELL; ANNOUNCES TOP-LINE RESULTS FROM EVO756 PHASE 2B TRIAL IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

路透·09/08/2026 21:58:53

登录查看新闻详情